{
    "clinical_study": {
        "@rank": "45291", 
        "arm_group": [
            {
                "arm_group_label": "XAF5 Gel", 
                "arm_group_type": "Experimental", 
                "description": "The patient will apply XAF5 Gel to the skin of the submental area once a night."
            }, 
            {
                "arm_group_label": "Placebo Gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The patient will apply a Placebo Gel to the skin of the submental area once a night."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test the effects of XAF5 Gel (applied to skin each night for 6 weeks) on\n      excess submental fat, also known as double chin.  The study will also assess the safety and\n      tolerability of XAF5 Gel."
        }, 
        "brief_title": "Phase 2a Study of XAF5 Gel for Reduction of Submental Fat", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Excess Submental Fat (\"Double Chin\")", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (paraphrased):\n\n          -  Adult men and women\n\n          -  Must understand and provide informed consent\n\n          -  Moderate submental fat (as determined by the clinician)\n\n          -  No laxity (looseness) or minimal laxity of submental skin\n\n          -  Healthy skin upon which a skin reaction would be visible\n\n        Exclusion Criteria (paraphrased):\n\n          -  A clinically significant health problem or recent illness\n\n          -  A clinically significant abnormal result on physical exam or laboratory tests\n\n          -  Neck or facial hair that would interfere with applying the study drug to submental\n             skin\n\n          -  Clinically significant skin disease\n\n          -  Body Mass Index (BMI) >= 40\n\n          -  Plan to begin a diet or weight loss regimen during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990326", 
            "org_study_id": "XAF5 B1"
        }, 
        "intervention": [
            {
                "arm_group_label": "XAF5 Gel", 
                "intervention_name": "XAF5 Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Gel", 
                "intervention_name": "Placebo Gel", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 10, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat", 
        "overall_official": {
            "affiliation": "Topokine Therapeutics", 
            "last_name": "Michael S Singer, M.D., Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in submental fat volume", 
            "safety_issue": "No", 
            "time_frame": "From Day 0 to Day 43"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990326"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "From Day 1 to Day 57"
        }, 
        "source": "Topokine Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Topokine Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}